Capstone Investment Advisors
HZNP

Capstone Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capstone Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-175,000
Closed -$20.2M – 2486
2023
Q3 		$20.2M Buy
175,000
+50,000
+40% +$5.37M 0.09% 149
2023
Q2 		$12.9M Buy
+125,000
New +$13.2M 0.06% 215
2023
Q1 		– Sell
-20,000
Closed -$2.28M – 1816
2022
Q4 		$2.28M Buy
+20,000
New +$1.66M 0.02% 665

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capstone Investment Advisors's HZNP Position: Q4 2023 in Review

Capstone Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 175,000 shares — an estimated $20.2M sold.

Capstone Investment Advisors first reported a position in HZNP in Q3 2016 and held it in 6 quarters. The position peaked at $30.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Capstone Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 175,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $20.2M.
  • Capstone Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 6 quarters.
  • Capstone Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.6M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Capstone Investment Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.